Anterior Segment Optical Coherence Tomography Analysis of Iris Morphometric Changes Induced by Prostaglandin Analogues Treatment in Patients with Primary Open Angle Glaucoma or Ocular Hypertension

Table 1: Descriptive statistics and iris thickness values measured in all three groups.

Variable	PG Group	NOPG Group	CTRL Group	ANOVA
Variable	(n=34, 68 eyes)	(n=30, 60 eyes)	(n=34, 68 eyes)	TEST p-value
Age (years)	66,60 ± 14,50	67,10 ± 10,76	64 ± 13,76	0,082
Sex	22 males	17 males	19 males	0,070
Sex	12 females	13 females	15 females	0,070
Iris thickness at DMR	0,51 ± 0,067	0,56 ± 0,057	0,55 ± 0,055	<0,0001
(mm)	0,51 ± 0,067	0,56 ± 0,057	0,55 ± 0,055	<0,0001
Iris thickness at SMR	0,59 ± 0,074	0,52 ± 0,049	0,52 ± 0,064	<0,0001
(mm)	0,59 ± 0,074	0,52 ± 0,049	0,52 ± 0,064	<0,0001
DMR/SMR ratio	0,88 ± 0,085	1,07 ± 0,099	1,07 ± 0,092	<0,0001

DMR, Dilator Muscle Region; SMR, Sphincter Muscle Region.
CTRL GROUP, healthy subjects; PG GROUP, patients treated with prostaglandin analogues.
NOPG GROUP, patients treated with hypotensive eyedrops different from prostaglandin analogues and alpha-adrenergic agonists.